Sign inCreate account

Report workspace tools

NCT01536249COMPLETEDanonymous

An Open-Label Study to Assess the Effect of Cimetidine on the Pharmacokinetics of Dexpramipexole (BIIB050) in Healthy Volunteers

Sponsor

Source record

Knopp Biosciences

Phase

Source record

Phase 1

Modality

AI-normalized

small molecule

Target

AI-normalized

Dexpramipexole targets the glutamate transporter EAAT2, which is implicated in neuroprotection and modulation of excitotoxicity, particularly relevant in neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS).

Indication / condition

AI-normalized

Amyotrophic Lateral Sclerosis

Intervention

Source record

Dexpramipexole, Cimetidine plus Dexpramipexole

Source & freshness

Source record

NCT ID

NCT01536249

Original source

ClinicalTrials.gov

Source last updated

Nov 25, 2014

Ingested at

Jun 12, 2026

Internal sync

Jun 12, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01536249

Title

An Open-Label Study to Assess the Effect of Cimetidine on the Pharmacokinetics of Dexpramipexole (BIIB050) in Healthy Volunteers

Sponsor

Knopp Biosciences

Status

COMPLETED

Phase

Phase 1

Condition raw

Amyotrophic Lateral Sclerosis

Condition normalized

Amyotrophic Lateral Sclerosis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Dexpramipexole targets the glutamate transporter EAAT2, which is implicated in neuroprotection and modulation of excitotoxicity, particularly relevant in neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS).

Target normalized

Dexpramipexole targets the glutamate transporter EAAT2, which is implicated in neuroprotection and modulation of excitotoxicity, particularly relevant in neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS).

Interventions

Dexpramipexole, Cimetidine plus Dexpramipexole

Public preview

Source record

Knopp Biosciences' study on dexpramipexole, an investigational drug for ALS, aims to elucidate the pharmacokinetic interactions with cimetidine. Given the increasing prevalence of ALS and the limited treatment options available, successful outcomes could position dexpramipexole favorably in a niche market. The study's completion in 2012 suggests that data may be available for further development or partnership opportunities. However, the competitive landscape includes other emerging therapies for ALS, necessitating a thorough analysis of dexpramipexole's unique value proposition and potential market differentiation.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

An Open-Label Study to Assess the Effect of Cimetidine on the Pharmacokinetics of Dexpramipexole (BIIB050) in Healthy Volunteers

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01536249

Status

COMPLETED

Phase

Phase 1

Sponsor

Knopp Biosciences

Executive brief

Investment-Ready Snapshot

Knopp Biosciences' study on dexpramipexole, an investigational drug for ALS, aims to elucidate the pharmacokinetic interactions with cimetidine. Given the increasing prevalence of ALS and the limited treatment options available, successful outcomes could position dexpramipexole favorably in a niche market. The study's completion in 2012 suggests that data may be available for further development or partnership opportunities. However, the competitive landscape includes other emerging therapies for ALS, necessitating a thorough analysis of dexpramipexole's unique value proposition and potential market differentiation.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedNov 25, 2014
Internal syncJun 12, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01536249

Indication

Amyotrophic Lateral Sclerosis

Modality

small molecule

Target

Dexpramipexole targets the glutamate transporter EAAT2, which is implicated in neuroprotection and modulation of excitotoxicity, particularly relevant in neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS).

Intervention

Dexpramipexole, Cimetidine plus Dexpramipexole

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.